Amgen leases 500,000 sq ft in Hyderabad to establish its first global capability centre, enhancing its office space in the ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Hyderabad: BioAsia 2025, the 22nd edition of what is touted as one of the largest gatherings of experts and global honchos ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

The On-Body Drug Delivery Devices market is witnessing significant growth, driven by the increasing demand for ...

Amgen’s Neulasta is set to face its first competition ... Fulphila was co-developed through a collaboration between Mylan and India’s Biocon that has produced 11 biologic and insulin products ...

Biosimilar Pipeline Analysis Market BURLINGAME, CA, UNITED STATES, February 6, 2025 /EINPresswire / -- The global Biosimilar Pip ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...